• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$9.79 -$0.11 (-1.11%)

REAL-TIME: Last trade at

ISIS Pharmaceuticals, Inc.

NASDAQ:ISIS

Jump to this page for:

Related Resources

Isis Pharmaceuticals to host conference call

5/23/2012 by Theflyonthewall.com

Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting

5/23/2012 by PR Newswire

Needham & Company Starts ISIS Pharmaceuticals (ISIS) at Buy; Looking Beyond Kynamro at Significant Pipeline Value

5/22/2012 by StreetInsider.com

Isis Pharmaceuticals initiated with a Buy at Needham

5/22/2012 by Theflyonthewall.com

5 Stocks Under $10 Poised for Breakouts

5/17/2012 by TheStreet.com

Isis Pharmaceuticals' Management Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)

5/15/2012 by Seeking Alpha

Isis Pharmaceuticals to Present A General Corporate Update at Its 2012 Annual Meeting of Stockholders and Open House

5/14/2012 by PR Newswire

Canaccord Genuity Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Adjusting Estimates After Top & Bottom Line Beat

5/9/2012 by StreetInsider.com

Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference

5/9/2012 by PR Newswire

Isis Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript

5/8/2012 by Seeking Alpha

Isis Pharmaceuticals reports Q1 EPS (24c), consensus (26c)

5/8/2012 by Theflyonthewall.com

Isis Pharmaceuticals' CEO Discusses Clinical Development Plans for ISIS-APOCIIIRx (Transcript)

5/4/2012 by Seeking Alpha

Biotechnology And Drugs Stocks To Watch Next Week

5/1/2012 by Seeking Alpha

Piper Jaffray Upgrades ISIS Pharmaceuticals (ISIS) to Overweight

5/1/2012 by StreetInsider.com

Isis Pharmaceuticals upgraded to Overweight from Neutral at Piper Jaffray

5/1/2012 by Theflyonthewall.com

Regulus Therapeutics Appoints Bruce Carter to its Board of Directors

4/30/2012 by PR Newswire

Webcast Alert: Isis Pharmaceuticals' First Quarter 2012 Financial Results Conference Call

4/25/2012 by PR Newswire

Rescheduled Webcast: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx

4/23/2012 by PR Newswire

Rescheduled Webcast: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx

4/23/2012 by StockWatch

Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx

4/18/2012 by PR Newswire

Isis Pharmaceuticals management to meet with BMO Capital

4/18/2012 by Theflyonthewall.com

Drug Information Association to host a conference

4/16/2012 by Theflyonthewall.com

Isis Pharmaceuticals management to meet with Jefferies

4/12/2012 by Theflyonthewall.com

Genzyme Corporation Submits Drug for Rare Cholesterol Disorder to FDA

3/30/2012 by BioSpace

Isis Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference

3/30/2012 by PR Newswire

Genzyme and Isis Announce Submission of U.S. NDA for KYNAMRO (mipomersen sodium) in Homozygous Familial Hypercholesterolemia

3/29/2012 by Genetic Engineering News

Genzyme, Isis submit NDA for Kynamro in HoFH, Isis gets $25M milestone payment

3/29/2012 by Theflyonthewall.com

Genzyme and Isis Announce Submission of U.S. NDA for KYNAMRO™ (mipomersen sodium) in Homozygous Familial Hypercholesterolemia

3/29/2012 by Business Wire

Canaccord Genuity Starts ISIS Pharmaceuticals (ISIS) at Hold

3/26/2012 by StreetInsider.com

Isis Pharmaceuticals management to meet with BMO Capital

3/22/2012 by Theflyonthewall.com

Webcast Alert: Isis Pharmaceuticals Hosts Dr. Raul Santos to Review KYNAMRO™ Data That Will Have Been Presented at ISA 2012 - XVI International Symposium on Atherosclerosis

3/22/2012 by PR Newswire

Isis Pharmaceuticals' Management Presents at Barclays Capital 2012 Global Healthcare Conference (Transcript)

3/20/2012 by Seeking Alpha

Isis Pharmaceuticals to Present at the Barclays Capital 2012 Global Healthcare Conference

3/8/2012 by PR Newswire

Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx

3/7/2012 by PR Newswire

Tekmira Pharma files motion to dismiss in patent infringement suit

3/6/2012 by Theflyonthewall.com

Isis Pharmaceuticals to Present at the 24th Annual ROTH Conference

3/5/2012 by PR Newswire

Isis Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

2/29/2012 by Seeking Alpha

Isis Pharmaceuticals expects to end FY12 with over $300M in cash

2/29/2012 by Theflyonthewall.com

Isis Pharmaceuticals, Inc. (ISIS) Posts Mixed Q4 Results

2/29/2012 by StreetInsider.com

Isis Pharmaceuticals reports Q4 EPS (20c), consensus (18c)

2/29/2012 by Theflyonthewall.com
See More Articles...